新京报调查发现，私立诊所和美容机构正在向健康人群违规注射NAD+处方药进行抗衰老 1。这些机构单次注射剂量高达150毫克至250毫克，超出法定安全剂量5毫克的30至50倍 1。消费者为此支付的费用在2980元至19800元之间 1。
注射后的不良反应令人担忧。32岁患者刘欣接受注射后出现心慌、胸闷、双臂血管灼烧感，随后连续多日失眠、头痛 1。更令人触目惊心的是，部分非医疗机构缺乏静脉注射资质，某些机构甚至使用明确标注"严禁用于人体"的化工级科研试剂在非无菌环境中自行配制 1。
从医学层面看，这一做法完全缺乏合规依据。国家未批准任何以"抗衰老"为适应证的辅酶Ⅰ静脉注射药品 1。中华医学会老年医学分会的相关共识推荐静脉给药方案为每日50毫克 1，远低于诊所实际使用的剂量。关于NAD+延缓衰老的研究绝大多数停留在动物实验阶段，至今尚未出现高质量大样本双盲临床试验 1。原料成本仅为几十元至150元每克，却以单次3000元至1万元的价格售出，利润空间巨大 1。目前该模式正通过招商加盟向多地复制扩散 1。
An investigation by Beijing News In-Depth has uncovered an underground market in which private clinics and beauty institutions are illegally administering NAD+ prescription medication to healthy individuals for anti-aging purposes, with single doses reaching 30 to 50 times the legally established safety threshold 1.
The legal safe dosage for NAD+ is 5 milligrams administered via intramuscular injection 1. However, clinics are injecting 150 to 250 milligrams per session, charging patients between 2,980 and 19,800 yuan per treatment 1. The profit margins are substantial, with raw material costs ranging from dozens of yuan to 150 yuan per gram, while the retail price per injection reaches 3,000 to 10,000 yuan 1. Adding to the danger, some non-medical institutions lack proper licensing to perform intravenous injections, and certain operators are mixing industrial-grade research-level reagents explicitly labeled "prohibited for human use" in non-sterile environments 1.
A 32-year-old patient named Liu Xin experienced heart palpitations, chest tightness, and a burning sensation in both arms following injection, followed by consecutive days of insomnia and headaches 1. The practice is expanding rapidly across multiple cities including Beijing, Shanghai, Nanjing, and Shenzhen through franchising models 1.
Despite the widespread promotion of NAD+ for anti-aging, the Chinese Medical Association's Geriatrics Branch recommends a daily intravenous dose of 50 milligrams 1. The majority of research on NAD+'s anti-aging effects remains limited to animal trials, with no high-quality, large-sample, double-blind clinical trials in humans 1. The Chinese government has not approved any NAD+ intravenous injection product with anti-aging as an approved therapeutic indication 1.
评论
还没有评论，欢迎留下第一条。